Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Metastatic Castration-Resistant Prostate Cancer
NCT03725761Phase 2Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Oct 2018
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Wisconsin–Madison. Primary endpoints: Prostate Specific Antigen Response Rate at 9 weeks and 6-Month Progression Free Survival Rate. Started Oct 2018; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03725761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725761.